Why You Can't Sleep on Peptides

Your body runs on glucose the way a car runs on fuel, and when the tank runs low at 2 AM, it doesn't just stall quietly.

It sets off an alarm.

That alarm is a hormonal rescue system, and understanding it is the key to understanding why peptides disrupt sleep for so many people who start using them.

When blood sugar drops below a certain threshold during the night, your brain detects the shortfall and signals the adrenal glands to release cortisol and adrenaline. These hormones tell your liver to produce more glucose through something called glycogenolysis, which is the breakdown of stored glycogen, and through something called gluconeogenesis, which is the liver manufacturing new glucose from non-carbohydrate sources like amino acids and glycerol. The result is blood sugar coming back up, and the cost is a sharp arousal from sleep. You wake at 2 or 3 AM feeling wired and anxious, and it has nothing to do with your sleep quality. Your nervous system just fired an emergency signal.

That's the whole mechanism.

Now the question is why peptides would make this happen in the first place, and the answer is different depending on which class of compound you're using.

The first class is something called GLP-1 receptor agonists and their multi-receptor variations, which includes semaglutide, tirzepatide, and retatrutide. These drugs work primarily by amplifying the body's incretin response, which is a system that was designed by evolution to regulate appetite, slow gastric emptying, and signal satiety. When you take them, hunger signals that would normally tell you to eat become dramatically quieter. In the phase 2 trial for retatrutide, participants at the highest dose lost an average of 24.2 percent of their body weight, which gives you a sense of just how much these compounds can suppress caloric intake.

The problem is that most people don't consciously compensate for this suppression. They eat less throughout the day because they don't feel hungry, and they go to bed with less stored fuel than their body needs to maintain stable blood sugar across eight hours of sleep. The gap between what was stored and what the body needs through the night is where the crash happens.

This is worth pausing on because a lot of people using these compounds assume they're fine because they're not hypoglycemic in a clinical sense. They're not diabetic. They don't pass out. But you don't need to hit a clinical threshold for your adrenal glands to respond. The cortisol system is sensitive, and even a moderate dip in the context of genuinely depleted glycogen stores is enough to trigger a partial arousal.

The second class works through a completely different mechanism. GH secretagogues like CJC-1295, ipamorelin, and tesamorelin stimulate the pituitary gland to release pulses of growth hormone, and growth hormone is something called an insulin antagonist, which means it directly opposes insulin's ability to move glucose into cells and suppresses the liver's sensitivity to insulin's signals.

The research here is quite specific. Studies suppressing nocturnal GH pulses with somatostatin abolished something called the dawn phenomenon, which is the rise in blood sugar that naturally occurs in the early morning hours, and when those GH pulses were artificially restored, hepatic glucose production increased by approximately 30 percent. The underlying mechanism involves growth hormone driving free fatty acid release from fat tissue, and those fatty acids compete with glucose for uptake in muscle and liver cells through a process described in the biochemistry literature as the Randle cycle. The result is insulin resistance that lasts for hours after the GH pulse fires.

So when you inject a secretagogue before bed and that GH pulse releases during slow-wave sleep, you get a sharp swing in the glucose-to-insulin relationship that can go either direction depending on your individual baseline and what you ate. Some people trend hyperglycemic, some people get a reactive dip, and either way the body responds with a counter-regulatory hormone release that breaks sleep.

If you're using both an incretin and a secretagogue at the same time, both of these mechanisms are running simultaneously. The incretin is keeping you undereating through the day, so you're going to bed with less stored fuel. The secretagogue is then disturbing the glucose-insulin relationship during the night. The compounding effect is why people stacking these compounds tend to report the worst sleep disruption.

The solutions follow directly from the mechanisms.

If you're on an incretin and undereating, the answer is making sure you're hitting your caloric floor even when you're not hungry, which can require deliberate, structured eating rather than relying on hunger signals that the drug has quieted. For people on low-carbohydrate diets, this concern is often less acute because the body has adapted to maintain blood sugar through gluconeogenesis rather than glycogen breakdown, but that adaptation only holds when total caloric intake is adequate. The problem isn't low carb. The problem is a drug-suppressed appetite on top of low carb with total calories genuinely too low.

If you're on a secretagogue, shifting the injection window a couple of hours earlier in the evening creates more separation between the GH pulse and the deepest stages of sleep. A small meal of protein and fat before bed, nothing large enough to spike insulin significantly, gives the liver enough substrate to sustain gluconeogenesis through the night without requiring a cortisol rescue to kick it off.

Both interventions are working toward the same goal, which is keeping the glucose-to-fuel ratio stable enough through the night that the adrenal system never needs to fire.

Most people chasing better sleep while on peptides are looking for a sleep solution, a different supplement, a different sleep environment, a different protocol for winding down, and none of it addresses the actual signal. The body isn't struggling to sleep. It's doing exactly what it was built to do when it detects a fuel crisis in the middle of the night.

The disruption isn't a side effect. It's a readout. And once you can read it correctly, fixing it becomes straightforward.

---

References

1. Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 diabetes mellitus by decreasing hepatic and extrahepatic sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990;331:52-59. Finding: Suppressing nocturnal GH spikes with somatostatin abolished the dawn phenomenon; restoring GH spikes reproduced it. Hepatic glucose production increased approximately 30%. Source
2. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;302:152-177. Finding: GH antagonizes insulin's hepatic and peripheral effects via increased free fatty acid flux and uptake. Source
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;3896:514-526. Finding: 24.2% mean weight loss at 12mg dose; significant appetite suppression documented across all dose groups. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness